Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
